The quadruplet KCRD (carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone) is safe and well tolerated as induction therapy for newly diagnosed, transplant eligible, myeloma patients

Saved in:
Bibliographic Details
Published inClinical lymphoma, myeloma and leukemia Vol. 15; p. e50
Main Authors Pawlyn, C, Davies, F, Cairns, D, Collett, C, Jones, J, Kaiser, M, Chalmers, A, Striha, A, Milligan, D, Lindsay, J, Chapman, C, Allotey, D, Shafeek, S, Karunanithi, K, Cook, G, Russell, N, Drayson, M, Owen, R, Gregory, W, Jackson, G, Morgan, G
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.09.2015
Subjects
Hematology, Oncology and Palliative Medicine
Online AccessGet full text

Cover

More Information
ISSN:2152-2650
2152-2669
DOI:10.1016/j.clml.2015.07.188